Stockreport

Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity [Seeking Alpha]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF NVO appears cheap due to high dependence on semaglutide and lack of near-term pipeline catalysts, justifying its discounted valuation. LLY is executing very well and [Read more]